Health · Pharma & Biotech · 1 hr ago

Tirzepatide Reduced BMI in Adolescents in a Phase III Trial

Tirzepatide Reduced BMI in Adolescents in a Phase III Trial

Tirzepatide reduced BMI substantially among adolescents in a phase III trial.

The SURMOUNT-ADOLESCENTS trial involved young people with obesity or overweight with related complications.

Tirzepatide is also known as Zepbound.

The findings concern changes in BMI, the outcome highlighted in the trial.

They add evidence about tirzepatide’s effects in adolescents, a group studied in this trial.

No next steps are stated in the available information.

1 source

Related